Display options
Cite
Naderi M, Yaghootkar H, Tara F, et al. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014;16(1):e11195doi: 10.5812/ircmj.11195.
Naderi, M., Yaghootkar, H., Tara, F., Tavakkol Afshari, J., Farid Hosseini, R., Ghayour Mobarhan, M., Shapouri Moghadam, A., Mirteimouri, M., & Tara, S. M. (2014). Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iranian Red Crescent medical journal, 16(1), e11195. https://doi.org/10.5812/ircmj.11195
Naderi, Mohammad, et al. "Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia." Iranian Red Crescent medical journal vol. 16,1 (2014): e11195. doi: https://doi.org/10.5812/ircmj.11195
Naderi M, Yaghootkar H, Tara F, Tavakkol Afshari J, Farid Hosseini R, Ghayour Mobarhan M, Shapouri Moghadam A, Mirteimouri M, Tara SM. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014 Jan;16(1):e11195. doi: 10.5812/ircmj.11195. Epub 2014 Jan 05. PMID: 24719701; PMCID: PMC3964419.
Copy Download .nbib Format: NLM
Share it on

Iran Red Crescent Med J. 2014 Jan;16(1):e11195. doi: 10.5812/ircmj.11195. Epub 2014 Jan 05.

Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia.

Iranian Red Crescent medical journal

Mohammad Naderi, Hanieh Yaghootkar, Fatemeh Tara, Jalil Tavakkol Afshari, Reza Farid Hosseini, Majid Ghayour Mobarhan, Abbas Shapouri Moghadam, Masoumeh Mirteimouri, Seyedeh Maryam Tara

Affiliations

  1. Mashhad University of Medical Sciences, Mashhad, IR Iran.
  2. Genetics of Complex Traits, University of Exeter, Heavitree Rd, Exeter, United Kingdom.
  3. Women Health Research Center, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  4. Immunology Research Center, Department of Immunogenetics, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  5. Cardiovascular Research Centre, Avicenna (Bu-Ali) Research Institute, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  6. Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

PMID: 24719701 PMCID: PMC3964419 DOI: 10.5812/ircmj.11195

Abstract

BACKGROUND: Preeclampsia is the most common serious disorder during pregnancy and studies show several immune-related processes in its pathophysiology. The role of cytokines and their expression remains controversial in this field. One of the cytokines of interest in recent studies has been TNF-α, which has been shown to have a higher level in maternal plasma of preeclamptic women.

OBJECTIVES: This study was designed to evaluate the role of TNF-α polymorphism at position -238 in the risk of developing preeclampsia during pregnancy.

PATIENTS AND METHODS: One hundred fifty three preeclamptic cases and 140 healthy pregnant women were retrieved from two major hospitals of Mashhad, Iran. Methods a case-control study were designed. Anyone with a history of inflammatory disease, hypertension, or chronic kidney disease was excluded. DNA was extracted from peripheral blood leukocytes. Both groups were genotyped for the polymorphism of the TNF-α gene at position -238 by the RFLP method with Ava II enzyme. Allele and genotype frequencies were compared using one-way ANOVA and the Fisher's exact test.

RESULTS: There were significant differences between the two groups in TNF-α genotype at position -238 (P < 0.001). In the preeclamptic group, the frequency of the AA genotype was higher (P < 0.001) and the frequency of the GG genotype was lower (P < 0.001). The overall prevalence of the A allele at position -238 was higher in preeclamptic cases (P < 0.001).

CONCLUSION: In this study group, TNF-α -238 polymorphism was shown to be different in preeclamptic and non-preeclamptic pregnant women. The AA genotype and the A allele may carry an increased risk for developing of preeclampsia.

Keywords: Polymorphism, Genetic; Pre-Eclampsia; Tumor Necrosis Factor-Alpha

References

  1. Am J Reprod Immunol. 2008 Aug;60(2):179-85 - PubMed
  2. J Assist Reprod Genet. 2002 May;19(5):220-3 - PubMed
  3. BMJ. 2011 Apr 07;342:d1875 - PubMed
  4. Placenta. 2009 Feb;30(2):111-23 - PubMed
  5. J Reprod Immunol. 1996 Dec;32(2):157-69 - PubMed
  6. J Matern Fetal Neonatal Med. 2013 May;26(7):680-5 - PubMed
  7. Am J Reprod Immunol. 2006 Feb;55(2):130-5 - PubMed
  8. J Matern Fetal Neonatal Med. 2012 Jun;25(6):826-30 - PubMed
  9. Cytokine. 2011 Dec;56(3):550-9 - PubMed
  10. Placenta. 2012 Mar;33(3):188-94 - PubMed
  11. Nucleic Acids Res. 1988 Feb 11;16(3):1215 - PubMed
  12. Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):547-51 - PubMed
  13. Hypertens Pregnancy. 2007;26(3):283-91 - PubMed
  14. Obstet Gynecol. 2002 Jan;99(1):159-67 - PubMed
  15. J Obstet Gynaecol Res. 2010 Feb;36(1):64-71 - PubMed
  16. Hypertension. 2005 Oct;46(4):1022-5 - PubMed
  17. Placenta. 1994 Dec;15(8):819-35 - PubMed
  18. Mol Hum Reprod. 2006 Oct;12(10):601-9 - PubMed
  19. Semin Immunopathol. 2007 Jun;29(2):151-62 - PubMed
  20. J Clin Endocrinol Metab. 2001 Jun;86(6):2505-12 - PubMed
  21. Br J Obstet Gynaecol. 1986 Sep;93(9):898-908 - PubMed
  22. Clin Dev Immunol. 2006 Jun-Dec;13(2-4):197-201 - PubMed
  23. Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):405-17 - PubMed
  24. Genes Immun. 2009 Oct;10(7):607-15 - PubMed
  25. Acta Med Okayama. 2007 Jun;61(3):153-60 - PubMed
  26. Placenta. 2001 Nov;22(10):822-30 - PubMed

Publication Types